Abstract Number: 2498 • 2018 ACR/ARHP Annual Meeting
The Association of Vitamin D with the Lipid Profile in Rheumatoid Arthritis: An Interplay Among Genetic Polymorphisms, DHCR7 Levels and Seasonality
Background/Purpose: Vitamin D deficiency is a common hallmark of rheumatic diseases, and some controversy exists about its effect on rheumatoid arthritis (RA), in particular about…Abstract Number: 2499 • 2018 ACR/ARHP Annual Meeting
Predictors of Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-Years Follow-up Study
Background/Purpose: Early treatment of RA improves longterm outcomes. However, at the beginning of the disease, some patients with RA fall within undifferentiated arthritis (UA) patients.…Abstract Number: 2500 • 2018 ACR/ARHP Annual Meeting
Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA
Background/Purpose: Anti-citrullinated protein antibody (ACPA) is a highly specific biomarker for RA1 and ACPA-seropositive patients have a tendency toward severe erosive disease and more rapid…Abstract Number: 2501 • 2018 ACR/ARHP Annual Meeting
Disease Activity Is the Major Discriminator When Defining Refractory Rheumatoid Arthritis
Disease Activity is the Major Discriminator When Defining Refractory Rheumatoid ArthritisM Bécède, JS Smolen, D Aletaha.Medical University of Vienna, Vienna, AustriaBackground/Purpose: Rheumatoid arthritis (RA) is…Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting
Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…Abstract Number: 2503 • 2018 ACR/ARHP Annual Meeting
Impact of Tobacco Smoking on 1-Year Mortality Following Total Hip and Total Knee Arthroplasty Among Rheumatoid Arthritis Patients – a Danish Cohort Study Using Nationwide Health Care Registers
Background/Purpose: Tobacco smoking and rheumatoid arthritis (RA) are independent risk factors for short-term complications following total hip and total knee arthroplasty (THA/TKA). We aimed to…Abstract Number: 2504 • 2018 ACR/ARHP Annual Meeting
A More Time Under Remission Impacts in a Better Health-Related Quality of Life in Rheumatoid Arthritis Mestizo Population
Background/Purpose: In Rheumatoid Arthritis (RA), sustained remission is associated with less disability (1,2) , and this outcome should be the goal in the RA treatment;…Abstract Number: 2505 • 2018 ACR/ARHP Annual Meeting
Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort
Background/Purpose: Variable outcomes in early rheumatoid arthritis (ERA) may be explained by heterogeneous latent disease activity trajectories, the predictors of which are not well defined.…Abstract Number: 2506 • 2018 ACR/ARHP Annual Meeting
The Joint Disease Burden in Patients with Secondary Sjögren’s Syndrome and RA Compared to Patients with RA Only
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered a poor prognostic factor in RA and is a common extra-articular manifestation of RA. We estimated prevalence of…Abstract Number: 2507 • 2018 ACR/ARHP Annual Meeting
Healthcare Resource Utilization in Patients with Secondary Sjögren’s Syndrome Associated with RA Compared with Patients with RA in an Insured Population
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is a rheumatic disease that may coexist with RA. Joint disease is more severe in patients (pts) with RA with…Abstract Number: 2508 • 2018 ACR/ARHP Annual Meeting
A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a debilitating chronic disease with an unmet need for additional therapeutic approaches. Bioelectronic therapy (BET), such as electrical neurostimulation of…Abstract Number: 2509 • 2018 ACR/ARHP Annual Meeting
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment
Background/Purpose: EXTEND (NCT01146652) is an ongoing open-label extension study enrolling patients completing five sarilumab originator studies (MOBILITY [NCT01061736]; TARGET [NCT01709578]; ASCERTAIN [NCT01768572]; ACT11575 [NCT01217814]; ONE…Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the effects…Abstract Number: 2511 • 2018 ACR/ARHP Annual Meeting
Benepali Switches in Clinical Practice – a Positive Single Centre Experience
Background/Purpose: Benepali (SB4) an etanercept (ETN) biosimilar, has demonstrated comparable efficacy in randomised controlled trials. Switching patients to biosimilars has cost benefits to the national…Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
ACR Meeting Abstracts